Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 8/20 | 0.44 |
| ▸ | APLNR | P35414 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12863942 | 0.84 | POLB (0.50) | SMN1; SMN2APLNRDHODH | |
| SCHEMBL197506 | 0.76 | CYP19A1 (0.64) | CYP1A2CYP19A1CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL12863944 | 0.75 | PTK2 (0.57) | SMN1; SMN2DHFRAPLNRKDM4EMTNR1A | |
| SCHEMBL13183083 | 0.74 | SMN1; SMN2 (0.49) | CYP1A2CYP19A1CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL12826507 | 0.74 | NR1H4 (0.51) | CYP1A2CYP19A1CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL21368786 | 0.73 | RAB9A (0.42) | SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL12653028 | 0.71 | LTA4H (0.61) | CYP1A2CYP19A1CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL2151432 | 0.70 | TSHR (0.69) | CYP1A2CYP19A1CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL17143201 | 0.70 | TSHR (0.69) | CYP1A2CYP19A1CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL17142884 | 0.70 | TSHR (0.69) | CYP1A2CYP19A1CYP2C9CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | MGLL, FAAH, FAAH2 | CYP1A2 1467/4885CYP19A1 1846/4885CYP2C9 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.